Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active
components of CMN-001 are autologous, matured dendritic cells, which have been
co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen
and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with
advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first
line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st
line failure.